做多
200% XENT
After conducting the research, I invested in and made over 200% on (XTLB) & (EYES), short % of float has been reduced to less than 1% of outstanding shares short currently.
Now investing in (XENT), has a short % of float of 6x larger (6.25%), total of 1,050,000 shares short, so may see an even lager gain.
Ears, Nose, Throat Devices Market to reach $26BB, with cumulative impact of COVID-19 SARS CoV2 variants, bio-absorbable therapies such as Propel & Sinuva fastest growing segment.
(See market report below)
(XENT) capturing 5% of market realize $1.3BB in revenues/ 32MM Shares = 40$ per share in Revenue, at comp. 10X Sales= $200 per share
(XENT) Intersect ENT Inc.
- Positive 10 day & 50 day Moving Average
- Current Assets to Liabilities ratio attractive
- Enterprise Value is undervalued compared to peer group
- 5 Day Rounding Bottom chart + (Cup & Handle)
- Moving Average Convergence Divergence crossing higher.
Christopher Michael Lim, MSc. Health Sciences
Western University Medical
Now investing in (XENT), has a short % of float of 6x larger (6.25%), total of 1,050,000 shares short, so may see an even lager gain.
Ears, Nose, Throat Devices Market to reach $26BB, with cumulative impact of COVID-19 SARS CoV2 variants, bio-absorbable therapies such as Propel & Sinuva fastest growing segment.
(See market report below)
(XENT) capturing 5% of market realize $1.3BB in revenues/ 32MM Shares = 40$ per share in Revenue, at comp. 10X Sales= $200 per share
(XENT) Intersect ENT Inc.
- Positive 10 day & 50 day Moving Average
- Current Assets to Liabilities ratio attractive
- Enterprise Value is undervalued compared to peer group
- 5 Day Rounding Bottom chart + (Cup & Handle)
- Moving Average Convergence Divergence crossing higher.
Christopher Michael Lim, MSc. Health Sciences
Western University Medical
免責聲明
這些資訊和出版物並非旨在提供，也不構成TradingView提供或認可的任何形式的財務、投資、交易或其他類型的建議或推薦。請閱讀使用條款以了解更多資訊。